Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Peter Black MD, FRCSC, FACS

Peter C. Black MD, FRCSC, FACS

Professor, Department of Urologic Sciences, University of British Columbia; Khosrowshahi Family Chair in Bladder Cancer Research; Senior Research Scientist, Vancouver Prostate Centre; Vancouver, BC, Canada

Peter Black is a Urologic Oncologist at Vancouver General Hospital, a Senior Research Scientist at the Vancouver Prostate Centre, and a Professor in the Department of Urologic Sciences at the University of British Columbia. He completed his urologic training at the University of Washington in Seattle and fellowship in Urologic Oncology at M.D. Anderson Cancer Center in Houston, Texas. He has a clinical subspecialty interest in prostate and bladder cancer and also a translational research program related primarily to bladder cancer. He is inaugural Editor-in-Chief of the SIU Journal.


Dr. Black reports the following: 
  • Member of an advisory board or equivalent with a commercial organization: 
    • AbbVie, AstraZeneca, Astellas, Bayer, Biosyent, BMS, EMD-Serono, Ferring, Fergene, H3-Biomedicine, Janssen, Merck, Protara Therapeutics, QED Bioscience, Roche, Sanofi, Sesen Bio, TerSera
  • Member of a speakers bureau:
    • AbbVie, Biosyent, Janssen, Ferring, TerSera, Pfizer
  • Recipient of grant(s) or an honorarium from a commercial organization:
    • iProgen, Sanofi, Bayer
  • Currently participating in or have participated in a clinical trial within the past two years:
    • Genentech, Janssen, BMS, Astellas, Sitka, MDx Health, AstraZeneca, Therelase, Pacific Edge
  • Shares a patent with (but have received no royalties from):
    • Decipher Biosciences